
Oxurion NV (OXUR) - Financial and Strategic SWOT Analysis Review
Description
Oxurion NV (OXUR) - Financial and Strategic SWOT Analysis Review
Table of Contents
44 Pages
- Section 1 - About the Company
- Oxurion NV - Key Facts
- Oxurion NV - Key Employees
- Oxurion NV - Key Employee Biographies
- Oxurion NV - Major Products and Services
- Oxurion NV - History
- Oxurion NV - Company Statement
- Oxurion NV - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Oxurion NV - Business Description
- Other Break-up: Income from Royalties
- Performance
- Other Break-up: Sales
- Performance
- Oxurion NV - Corporate Strategy
- Oxurion NV - SWOT Analysis
- SWOT Analysis - Overview
- Oxurion NV - Strengths
- Oxurion NV - Weaknesses
- Oxurion NV - Opportunities
- Oxurion NV - Threats
- Oxurion NV - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
- Oxurion NV, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
- Oxurion NV, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Apr 10, 2024: Oxurion Receives EUR 450,000 in the Framework of the Atlas Funding Program : Eleventh Tranche Fully Issued and Paid-up
- Mar 05, 2024: Oxurion Receives EUR 300,000 in the Framework of the Atlas Funding Program Tenth Tranche Fully Issued and Paid-Up
- Sep 29, 2023: Oxurion Publishes First Half 2023 Results
- May 15, 2023: Oxurion Announces Results of the Annual Shareholders’ Meeting of 2 May 2023
- Mar 31, 2023: Oxurion Publishes 2022 Annual Report
- Mar 14, 2023: Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Oxurion NV, Key Facts
- Oxurion NV, Key Employees
- Oxurion NV, Key Employee Biographies
- Oxurion NV, Major Products and Services
- Oxurion NV, History
- Oxurion NV, Subsidiaries
- Oxurion NV, Key Competitors
- Oxurion NV, Ratios based on current share price
- Oxurion NV, Annual Ratios
- Oxurion NV, Annual Ratios (Cont...1)
- Oxurion NV, Annual Ratios (Cont...2)
- Oxurion NV, Interim Ratios
- Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
- Oxurion NV, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
- Oxurion NV, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Oxurion NV, Performance Chart (2019 - 2023)
- Oxurion NV, Ratio Charts
- Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
- Oxurion NV, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.